How ‘New Science’ Is Changing Healthcare
If there’s one good thing that’s come from the pandemic, it’s this: Scientists and drug manufacturers came together in record time and with a shared purpose to create a safe and effective Covid-19 vaccine. In doing so, they set a precedent for medical advancements. So, where do we go from here? In this episode, we’ll talk about how biopharma companies can learn from last year’s disruption and harness what Accenture calls ‘New Science’ to rapidly discover and deliver revolutionary treatments and preparing for in the midst of regulatory and economic shifts. We’ll speak with Chris Gibson, C.E.O. and Co-Founder at Recursion; Stuart Henderson, Global Industry Lead — Life Sciences at Accenture; and David Coman, C.E.O at Science 37.
Audio is streamed directly from the publisher (nyt.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
If there’s one good thing that’s come from the pandemic, it’s this: Scientists and drug manufacturers came together in record time and with a shared purpose to create a safe and effective Covid-19 vaccine. In doing so, they set a precedent for medical advancements. So, where do we go from here? In this episode, we’ll talk about how biopharma companies can learn from last year’s disruption and harness what Accenture calls ‘New Science’ to rapidly discover and deliver revolutionary treatments and preparing for in the midst of regulatory and economic shifts. We’ll speak with Chris Gibson, C.E.O. and Co-Founder at Recursion; Stuart Henderson, Global Industry Lead — Life Sciences at Accenture; and David Coman, C.E.O at Science 37.
This week's guests:
Chris Gibson, C.E.O. and Co-Founder at Recursion
Stuart Henderson, Global Industry Lead — Life Sciences at Accenture
David Coman, C.E.O at Science 37
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.